Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 19, Issue 10, Pages 1325-1330Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2021.1908127
Keywords
SARS-CoV-2; prevention; Hypromellose; nasal spray; low pH
Ask authors/readers for more resources
The city of Bney Brak in Israel had the highest COVID-19 infection rate and mortality. A study found that using Taffix, an innovative nasal powder, could reduce the risk of SARS CoV2 infection. This suggests that Taffix could be an additional tool in preventing the spread of COVID-19.
Objectives: Bney Brak city tops Israel's COVID-19 infection rate and mortality. Before the Jewish New Year (two-day gathering) SARS-CoV-2 PCR positivity rates were 17.6% and reached 28.1% two weeks later Taffix - an innovative nasal powder creates a protective gel over the nasal mucosa blocking viruses from infecting nasal cells, was tested for efficacy in preventing SARS CoV2 infection. Methods: In a prospective users survey, 243 members of an ultra-orthodox community that participated in two days prayers were followed for 14 days following this 'superspread' event. Eighty-three used Taffix throughout holiday's prayers and the following two weeks (ITT). Eighty-one used it regularly (PP). Two used it rarely if at all. The remaining 160 did not use Taffix. Results: After 14 days, 0/81 (0%) of (PP) Tafffix users, 2/83 (2.4%) of (ITT) Taffix users and 16/160 (10%) nonusers were infected. Odds ratio for infection among Taffix users was 0.22, a reduction of 78% (95%CI 1%-95%). No side effects reported. Conclusion: Taffix could be an additional tool against COVID19 spread, in addition to recommended safety measures. This is the first time that a prevention measure of SARS-CoV-2, beyond the use of masks, has proved effective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available